NCT07560150Phase 2, phase 3Completed

Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar/Interchangeable Rapid-Acting Insulin Aspart (I004) and NovoLog® After Single-Dose Subcutaneous Administration to Healthy Volunteers

Study sponsor: Amphastar Pharmaceuticals, Inc. · AMPH

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2026-06-22Actual
Enrollment · participants62Actual
Source updated2026-07-22Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 5 fields changed

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 60 participants (planned). After: 62 participants (actual).

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: Jun 2026. After: 22 Jun 2026.

Recruitment status changed

Before: Recruiting. After: Completed.

Check registry source